Merck Receivables 2010-2024 | MKKGY

Merck receivables for the quarter ending September 30, 2024 were $4.777B, a 7.59% decline year-over-year.

  • Merck receivables for 2023 were $4.845B, a 0.85% increase from 2022.
  • Merck receivables for 2022 were $4.804B, a 1.86% decline from 2021.
  • Merck receivables for 2021 were $4.896B, a 14.56% increase from 2020.

Merck Receivables 2010-2024 | MKKGY

  • Merck receivables for 2023 were $4.845B, a 0.85% increase from 2022.
  • Merck receivables for 2022 were $4.804B, a 1.86% decline from 2021.
  • Merck receivables for 2021 were $4.896B, a 14.56% increase from 2020.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$74.8B
Chugai Pharmaceutical (CHGCY)$70.2B
Takeda Pharmaceutical (TAK)$41.1B
Sandoz Group AG (SDZNY)$19.6B
Astellas Pharma (ALPMY)$17.3B
United Therapeutics (UTHR)$16B
Neurocrine Biosciences (NBIX)$14.5B
Summit Therapeutics (SMMT)$14B
Shionogi (SGIOY)$12.1B
Orion OYJ (ORINY)$7.2B
Stevanato Group S.p.A (STVN)$6.9B
Madrigal Pharmaceuticals (MDGL)$6.4B
Corcept Therapeutics (CORT)$5.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Grifols, S.A (GRFS)$5B
Ionis Pharmaceuticals (IONS)$5B
Crinetics Pharmaceuticals (CRNX)$3.5B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Recursion Pharmaceuticals (RXRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.2B
Soleno Therapeutics (SLNO)$2B
Centessa Pharmaceuticals (CNTA)$2B
Hypermarcas (HYPMY)$1.9B
Indivior (INDV)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Evotec AG (EVO)$1.5B
Dyne Therapeutics (DYN)$1.4B
Xencor (XNCR)$1.3B
Guardian Pharmacy Services (GRDN)$1.3B